Comments
Shares of Natco Pharma Ltd climbed as much as 8.3 per cent to Rs 734, their biggest intraday percentage gain since October 5, 2017. The stock hit its highest level since October 4.
According to the company, an US court has affirmed Teva's Copaxone patents as invalid. US marketing partner Mylan NV has won against Teva Pharmaceuticals Ltd, culminating its defence of patent infringement cases in the US.
More than 306,000 shares changed hands, vs 30-day moving average of 284,288 shares. Natco Pharma stock had fallen 29.5 per cent this year as of last close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.